TBPH
Theravance Biopharma Inc · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +8.0% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 78 | 0 | 20.06M | $340.93M | +5 | −5 |
| Q1 2026 | 81 | 0 | 20.48M | $332.45M | +7 | −7 |
| Q4 2025 | 81 | +1 | 20.44M | $382.41M | +1 | — |
| Q3 2025 | 17 | 0 | 12.34M | $180.13M | +1 | −1 |
| Q2 2025 | 14 | +1 | 10.14M | $111.79M | +2 | −1 |
| Q1 2025 | 10 | +2 | 4.07M | $36.36M | +2 | — |
| Q4 2024 | 8 | 0 | 3.76M | $35.35M | — | — |
| Q3 2024 | 7 | -2 | 2.37M | $19.08M | — | −2 |
| Q2 2024 | 9 | — | 6.87M | $58.23M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 4.07M | -1.7% | $59.41M | 0.0% | ▼ Trim | 2 | SEC ↗ ×11 |
| 2 | The Vanguard Group ✦ (passive) | 2.21M | +2.5% | $32.29M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 3 | D. E. Shaw & Co. ✦ | 1.21M | +20.7% | $17.66M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 4 | State Street Global Advisors ✦ (passive) | 1.06M | +2.0% | $15.42M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 897.99K | +0.5% | $13.11M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 6 | Arrowstreet Capital ✦ | 726.78K | New | $10.61M | 0.0% | New | 1 | SEC ↗ |
| 7 | Morgan Stanley ✦ | 599.55K | — | $8.75M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 8 | JPMorgan Chase ✦ | 426.21K | — | $6.22M | 0.0% | n/c | 1 | SEC ↗ ×12 |
| 9 | Marshall Wace ✦ | 357.65K | +254.9% | $5.22M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 10 | Goldman Sachs Group ✦ | 258.65K | — | $3.78M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 11 | Two Sigma Investments ✦ | 231.27K | +1199.9% | $3.38M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | Wellington Management ✦ | 130.15K | -22.3% | $1.90M | 0.0% | ▼ Trim | 6 | SEC ↗ ×3 |
| 13 | T. Rowe Price ✦ | 64.14K | +2.7% | $937,000 | 0.0% | ▲ Add | 6 | SEC ↗ |
| 14 | Citadel Advisors ✦ | 50.87K | -89.5% | $742,659 | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 15 | Millennium Management ✦ | 24.49K | -44.1% | $357,583 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 18.84K | +53.8% | $274,990 | 0.0% | ▲ Add | 3 | SEC ↗ ×5 |
| 17 | Fidelity (FMR) ✦ | 4.72K | -4.0% | $68,897 | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Arrowstreet Capital | $10.61M | 0.0% |
Exited
| Point72 Asset Management | $139,991 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 170 holders, 49.68M shares, $776.87M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 3.33K sh · $56,707
Officer · 3.33K sh · $56,690
Officer · 6.66K sh · $113,397
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology